| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec8277d9dd2f566d41ab3d1931b607ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3127c0ebee3f865b211b019fac84286 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_021c3f58abee3b674dfc832adc5b6198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6036df3f2a4653daf8d7ab8334125f0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b77b94471493906b106a982bb85aca3 |
| publicationDate |
2022-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022184066-A1 |
| titleOfInvention |
Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
| abstract |
This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m 2 to 5 mg/m 2 of a compound having the structure n n n n n n n n n n or a salt, zwitterion, or ester thereof. |
| priorityDate |
2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |